Market Cap | 125.09M | P/E | 19.16 | EPS this Y | 16.30% | Ern Qtrly Grth | - |
Income | -16.78M | Forward P/E | 66.18 | EPS next Y | 158.50% | 50D Avg Chg | -6.00% |
Sales | 44.38M | PEG | - | EPS past 5Y | 389.90% | 200D Avg Chg | -16.00% |
Dividend | N/A | Price/Book | 2.05 | EPS next 5Y | - | 52W High Chg | -45.00% |
Recommedations | 2.00 | Quick Ratio | 1.97 | Shares Outstanding | 19.08M | 52W Low Chg | 10.00% |
Insider Own | 22.06% | ROA | -15.05% | Shares Float | 14.05M | Beta | -0.27 |
Inst Own | 9.51% | ROE | -29.70% | Shares Shorted/Prior | 274.69K/248.19K | Price | 7.28 |
Gross Margin | 36.59% | Profit Margin | -37.81% | Avg. Volume | 66,377 | Target Price | 21.00 |
Oper. Margin | -324.44% | Earnings Date | May 9 | Volume | 19,951 | Change | -2.67% |
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
HC Wainwright & Co. | Buy | Feb 21, 24 |
HC Wainwright & Co. | Buy | Nov 10, 23 |
HC Wainwright & Co. | Buy | Aug 14, 23 |
HC Wainwright & Co. | Buy | Jun 2, 23 |
HC Wainwright & Co. | Buy | May 12, 23 |
HC Wainwright & Co. | Buy | Mar 8, 23 |
HC Wainwright & Co. | Buy | Feb 23, 23 |
HC Wainwright & Co. | Buy | Feb 16, 23 |
HC Wainwright & Co. | Buy | Feb 7, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Karkus Ted William | CEO & CHAIRMAN CEO & CHAIRMAN | Oct 16 | Option | 0.6 | 600,000 | 360,000 | 3,388,609 | 10/18/22 |
Karkus Ted William | CEO & CHAIRMAN CEO & CHAIRMAN | Aug 10 | Option | 0.6 | 600,000 | 360,000 | 3,105,214 | 08/10/22 |
Karkus Ted William | CEO & CHAIRMAN CEO & CHAIRMAN | May 23 | Option | 2 | 450,000 | 900,000 | 2,783,471 | 05/25/22 |
Brady Monica L. | Chief Accounting Off.. Chief Accounting Officer | May 23 | Option | 2.67 | 39,250 | 104,798 | 46,678 | 05/25/22 |
Barr Jason Michael | Director Director | Mar 10 | Buy | 6.48 | 721 | 4,672 | 30,962 | 04/11/22 |